Novan Inc
F:6LUA

Watchlist Manager
Novan Inc Logo
Novan Inc
F:6LUA
Watchlist
Price: 0.001 EUR Market Closed
Market Cap: €1.3k

Novan Inc
PP&E Net

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Novan Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Novan Inc
F:6LUA
PP&E Net
$15.6m
CAGR 3-Years
8%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
PP&E Net
$22.3B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
PP&E Net
$9B
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
8%
Pfizer Inc
NYSE:PFE
PP&E Net
$18.9B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
PP&E Net
$25.6B
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
PP&E Net
$22.3B
CAGR 3-Years
34%
CAGR 5-Years
22%
CAGR 10-Years
11%
No Stocks Found

Novan Inc
Glance View

Market Cap
1.3k EUR
Industry
Pharmaceuticals

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.

6LUA Intrinsic Value
Not Available

See Also

What is Novan Inc's PP&E Net?
PP&E Net
15.6m USD

Based on the financial report for Dec 31, 2022, Novan Inc's PP&E Net amounts to 15.6m USD.

What is Novan Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
-1%

Over the last year, the PP&E Net growth was 13%. The average annual PP&E Net growth rates for Novan Inc have been 8% over the past three years , -1% over the past five years .

Back to Top